Przewlekła choroba ziarniniakowa – Rokowania, prognozy i postęp choroby

Przewlekła choroba ziarniniakowa
Rokowania, prognozy i postęp choroby

Przewlekła choroba ziarniniakowa (CGD) jest pierwotnym niedoborem odporności wynikającym z defektu oksydazy NADPH, co prowadzi do upośledzenia wybuchu tlenowego w fagocytach. Rokowanie u pacjentów z CGD uległo znaczącej poprawie dzięki wprowadzeniu profilaktyki przeciwdrobnoustrojowej, leków przeciwgrzybiczych (azole) oraz interferonu gamma. Obecnie 50% pacjentów przeżywa do trzeciej dekady życia, a roczny wskaźnik śmiertelności wynosi 1,5% dla formy autosomalnej recesywnej i 5% dla sprzężonej z chromosomem X. Czynniki prognostyczne obejmują wiek wystąpienia objawów (lepsze rokowanie po 1. roku życia), typ dziedziczenia (cięższy przebieg w formie sprzężonej z X) oraz resztkową produkcję reaktywnych form tlenu (ROI), która koreluje z nasileniem objawów i przeżywalnością. Infekcje, zwłaszcza inwazyjna aspergiloza i ciężkie infekcje bakteryjne, pozostają główną przyczyną zgonów.

Przewidywanie wyników leczenia i rokowanie w przewlekłej chorobie ziarniniakowej

Wskaźniki przeżycia i czynniki prognostyczne
Główne przyczyny zachorowalności i umieralności
Wpływ leczenia na rokowanie
Przeszczepienie hematopoetycznych komórek macierzystych jako opcja leczenia przyczynowego
Jakość życia i ogólne rokowanie
Kolejne rozdziały

Przewidywanie wyników leczenia i rokowanie w przewlekłej chorobie ziarniniakowej

Przewlekła choroba ziarniniakowa (ang. Chronic Granulomatous Disease, CGD) to pierwotny niedobór odporności spowodowany defektami w którymkolwiek z pięciu podjednostek kompleksu oksydazy NADPH, odpowiedzialnej za wybuch tlenowy w fagocytujących leukocytach. Rokowanie w tej chorobie znacznie się poprawiło na przestrzeni lat, jednak nadal pozostaje istotnym wyzwaniem medycznym.¹

Wskaźniki przeżycia i czynniki prognostyczne

Wskaźniki przeżycia w przewlekłej chorobie ziarniniakowej wykazują znaczną poprawę w ostatnich dekadach, jednak nadal pozostają poniżej oczekiwanej długości życia w populacji ogólnej. Analiza aktuarialna wykazała 50% przeżywalność pacjentów przez trzecią dekadę życia.² Obecnie, dzięki wprowadzeniu rutynowej profilaktyki przeciwdrobnoustrojowej oraz leków przeciwgrzybiczych z grupy azoli, ogólna przeżywalność uległa znacznej poprawie.³

Zidentyfikowano kilka istotnych czynników prognostycznych wpływających na przebieg choroby i przeżywalność:

Wiek wystąpienia objawów – długoterminowe przeżycie pacjentów, u których objawy rozwinęły się po pierwszym roku życia, jest znacząco lepsze niż u pacjentów, których choroba zaczęła się w niemowlęctwie⁴⁵
Typ dziedziczenia – pacjenci z formą sprzężoną z chromosomem X mają zwykle cięższą postać choroby niż chorzy z autosomalnie recesywną CGD⁶⁷
Resztkowa produkcja reaktywnych form tlenu (ROI) – pacjenci z umiarkowaną resztkową produkcją ROI mają mniej nasilone objawy choroby i większe prawdopodobieństwo długoterminowego przeżycia⁸

Główne przyczyny zachorowalności i umieralności

Pomimo poprawy w zakresie leczenia i opieki, infekcje pozostają główną przyczyną zgonów pacjentów z CGD. Nieleczone infekcje związane z przewlekłą chorobą ziarniniakową mogą być śmiertelne.⁹ Szczególnie zagrażające życiu są:

Infekcje grzybicze, zwłaszcza inwazyjna aspergiloza, która pozostaje istotnym czynnikiem determinującym przeżycie¹⁰¹¹
Ciężkie, zagrażające życiu infekcje bakteryjne, których ryzyko utrzymuje się przez całe życie, choć są one rzadsze u dorosłych niż u dzieci¹²
Powikłania ziarniniakowe, które mogą prowadzić do znacznej chorobowości¹³

Obecnie roczny wskaźnik śmiertelności wynosi 1,5% rocznie dla osób z autosomalnie recesywną CGD oraz 5% dla pacjentów z CGD sprzężoną z chromosomem X.¹⁴

Wpływ leczenia na rokowanie

Od czasu wprowadzenia profilaktycznego stosowania antybiotyków, leków przeciwgrzybiczych oraz interferonu gamma (INF-gamma), rokowanie dla pacjentów z CGD uległo poprawie. Coraz częściej pacjenci dożywają czwartej i piątej dekady życia.¹⁵ Obecnie dostępne opcje terapeutyczne mają znaczący wpływ na poprawę rokowania:

Profilaktyka przeciwdrobnoustrojowa i przeciwgrzybicza – znacząco zmniejsza ryzyko infekcji¹⁶
Szybkie rozpoznanie i leczenie infekcji – kluczowe w zapobieganiu powikłaniom zagrażającym życiu¹⁷
Przeszczepienie hematopoetycznych komórek macierzystych (HCT) – obecnie jedyna metoda leczenia przyczynowego¹⁸

Przeszczepienie hematopoetycznych komórek macierzystych jako opcja leczenia przyczynowego

Przeszczepienie hematopoetycznych komórek macierzystych (HCT) jest obecnie jedyną opcją leczenia przyczynowego przewlekłej choroby ziarniniakowej. Wyniki transplantacji uległy znacznej poprawie w ostatnich dekadach, z odsetkiem ogólnego przeżycia sięgającym obecnie 90% u dzieci poniżej 14 roku życia.¹⁹

Przeżywalność po HCT wzrosła z około 85% przed rokiem 2000 do ponad 90% według najnowszych doniesień, a wyniki są obiecujące niezależnie od źródła dawcy. W związku z tym, HCT powinno być rozważane u wszystkich pacjentów z CGD, niezależnie od płci, mutacji genetycznej i objawów klinicznych.²⁰

Aktualne dane sugerują, że kondycjonowanie mieloablacyjne prowadzi do bardziej trwałego wszczepienia komórek mieloidalnych, ale wiąże się ze zwiększoną toksycznością i wysokim odsetkiem choroby przeszczep przeciwko gospodarzowi (GVHD).²¹ W miarę jak HCT staje się bardziej dostępne i lepiej tolerowane, oczekuje się, że ogólna długość życia pacjentów z CGD znacznie wzrośnie w ciągu najbliższych kilku lat.²²

Jakość życia i ogólne rokowanie

Pomimo wyzwań związanych z CGD, przy odpowiednim leczeniu i wsparciu, rokowanie dla większości pacjentów jest relatywnie dobre. Wiele osób z CGD prowadzi aktywne i satysfakcjonujące życie.²³

Kluczowe aspekty wpływające na jakość życia i rokowanie obejmują:

Szybkie rozpoznawanie i leczenie infekcji zanim staną się ciężkie lub zagrażające życiu²⁴
Ciągłe leczenie i monitorowanie w celu zapobiegania i kontrolowania infekcji oraz stanów zapalnych²⁵
Kompleksowa opieka multidyscyplinarna²⁶

Należy podkreślić, że ciężkość CGD nie jest jednolita, a rokowanie dotyczące długoterminowego przeżycia jest lepsze niż sugerowano we wcześniejszych doniesieniach.²⁷ W przypadku braku leczenia przyczynowego istotne jest prowadzenie badań oceniających skuteczność interferonu gamma oraz oferowanie wczesnej diagnostyki prenatalnej jak największej liczbie dotkniętych rodzin.²⁸

Podsumowując, choć przewlekła choroba ziarniniakowa pozostaje poważnym schorzeniem, znaczny postęp w leczeniu i opiece nad pacjentami doprowadził do znaczącej poprawy rokowania i jakości życia. Wczesna diagnoza, odpowiednia profilaktyka i leczenie, a w wybranych przypadkach przeszczepienie hematopoetycznych komórek macierzystych, oferują pacjentom z CGD coraz lepsze perspektywy na przyszłość.²⁹

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

Materiały źródłowe

#1 A Review of Chronic Granulomatous Disease
https://pmc.ncbi.nlm.nih.gov/articles/PMC5709447/
Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by defects in any of the five subunits of the NADPH oxidase complex responsible for the respiratory burst in phagocytic leukocytes. […] The implementation of routine antimicrobial prophylaxis and the advent of azole antifungals has considerably improved overall survival. Nevertheless, life expectancy remains decreased compared to the general population. […] At present, hematopoietic stem cell transplantation (HCT) is the only curative treatment, and transplantation outcomes have improved over the last few decades with overall survival rates now 90% in children less than 14 years of age. […] The current evidence suggests that myeloablative conditioning results in more durable myeloid engraftment but with increased toxicity and high rates of graft-versus-host disease.
#2 Prognosis of chronic granulomatous disease – PubMed
https://pubmed.ncbi.nlm.nih.gov/2221966/
The records of 28 patients with chronic granulomatous disease born over a 32 year period were reviewed. Nine patients were known to have died, in most cases of progressive suppurative infection. Actuarial analysis showed 50% survival through the third decade of life. The long term survival of patients developing symptoms after the end of the first year of life was significantly better than that of patients whose illness started in infancy. Our data confirm that the severity of chronic granulomatous disease is not uniform, and that the prognosis for long term survival is better than that suggested in earlier reports. […] Early onset may be a poor prognostic sign and invasive aspergillosis is a life threatening complication. In the absence of curative treatment, trials to assess the effectiveness of interferon gamma are necessary and early antenatal diagnosis should be offered to as many affected families as possible.
#3 A Review of Chronic Granulomatous Disease
https://pmc.ncbi.nlm.nih.gov/articles/PMC5709447/
Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by defects in any of the five subunits of the NADPH oxidase complex responsible for the respiratory burst in phagocytic leukocytes. […] The implementation of routine antimicrobial prophylaxis and the advent of azole antifungals has considerably improved overall survival. Nevertheless, life expectancy remains decreased compared to the general population. […] At present, hematopoietic stem cell transplantation (HCT) is the only curative treatment, and transplantation outcomes have improved over the last few decades with overall survival rates now 90% in children less than 14 years of age. […] The current evidence suggests that myeloablative conditioning results in more durable myeloid engraftment but with increased toxicity and high rates of graft-versus-host disease.
#4 Prognosis of chronic granulomatous disease – PubMed
https://pubmed.ncbi.nlm.nih.gov/2221966/
The records of 28 patients with chronic granulomatous disease born over a 32 year period were reviewed. Nine patients were known to have died, in most cases of progressive suppurative infection. Actuarial analysis showed 50% survival through the third decade of life. The long term survival of patients developing symptoms after the end of the first year of life was significantly better than that of patients whose illness started in infancy. Our data confirm that the severity of chronic granulomatous disease is not uniform, and that the prognosis for long term survival is better than that suggested in earlier reports. […] Early onset may be a poor prognostic sign and invasive aspergillosis is a life threatening complication. In the absence of curative treatment, trials to assess the effectiveness of interferon gamma are necessary and early antenatal diagnosis should be offered to as many affected families as possible.
#5 Chronic Granulomatous Disease: Practice Essentials, Background, Pathophysiology
https://emedicine.medscape.com/article/1116022-overview
The long-term survival of patients who develop symptoms after the end of the first year of life is significantly better than that of patients whose illness starts in infancy. Survival rates are variable but improving; approximately 50% of patients survive to age 30-40 years. Infections are less common in adults than in children, but the propensity for severe life-threatening bacterial infections persists throughout life. […] Fungal infections remain a major determinant of survival in chronic granulomatous disease (CGD). Morbidity secondary to infection or granulomatous complications remains significant for many patients, particularly those with the X-linked form. X-linked patients generally have more severe disease, and this is generally in those with lower residual superoxide production. Survival in CGD has increased over the years, but infections are still major causes of morbidity and mortality. Currently, the annual mortality rate is 1.5% per year for persons with autosomal recessive CGD and 5% for those with X-linked CGD.
#6 Chronic Granulomatous Disease: Practice Essentials, Background, Pathophysiology
https://emedicine.medscape.com/article/1116022-overview
The long-term survival of patients who develop symptoms after the end of the first year of life is significantly better than that of patients whose illness starts in infancy. Survival rates are variable but improving; approximately 50% of patients survive to age 30-40 years. Infections are less common in adults than in children, but the propensity for severe life-threatening bacterial infections persists throughout life. […] Fungal infections remain a major determinant of survival in chronic granulomatous disease (CGD). Morbidity secondary to infection or granulomatous complications remains significant for many patients, particularly those with the X-linked form. X-linked patients generally have more severe disease, and this is generally in those with lower residual superoxide production. Survival in CGD has increased over the years, but infections are still major causes of morbidity and mortality. Currently, the annual mortality rate is 1.5% per year for persons with autosomal recessive CGD and 5% for those with X-linked CGD.
#7 Chronic Granulomatous Disease Indicators and Life Expectancy – An HCP Resource
https://www.cgdpathways.com/cgd-overview/about-chronic-granulomatous-disease
Life expectancy remains well below that of the general population. Although survival has increased, infections are still the major causes of mortality for patients with CGD. Left untreated, CGD-related infections may be fatal. […] The survival curve of the general US population has been included for comparison. Graph showing the survival rates over time for X-linked and autosomal recessive CGD patients compared to the general US population, with X-linked patients showing worse survival than autosomal recessive patients.
#8 Chronic Granulomatous Disease: Practice Essentials, Background, Pathophysiology
https://emedicine.medscape.com/article/1116022-overview
Since the advent of prophylactic antibiotics, antifungals, and interferon-gamma (INF-gamma), the prognosis for patients with CGD has improved. Patients living to their 30s and 40s is now common. […] Patients with CGD and modest residual production of reactive oxygen intermediates (ROIs) have significantly less severe illness and a greater likelihood of long-term survival than patients with little residual ROI production. The production of residual ROI is predicted by the specific NADPH oxidase mutation, regardless of the specific gene affected, and is a predictor of survival in patients with CGD.
#9 Chronic Granulomatous Disease Indicators and Life Expectancy – An HCP Resource
https://www.cgdpathways.com/cgd-overview/about-chronic-granulomatous-disease
Life expectancy remains well below that of the general population. Although survival has increased, infections are still the major causes of mortality for patients with CGD. Left untreated, CGD-related infections may be fatal. […] The survival curve of the general US population has been included for comparison. Graph showing the survival rates over time for X-linked and autosomal recessive CGD patients compared to the general US population, with X-linked patients showing worse survival than autosomal recessive patients.
#10 Prognosis of chronic granulomatous disease – PubMed
https://pubmed.ncbi.nlm.nih.gov/2221966/
The records of 28 patients with chronic granulomatous disease born over a 32 year period were reviewed. Nine patients were known to have died, in most cases of progressive suppurative infection. Actuarial analysis showed 50% survival through the third decade of life. The long term survival of patients developing symptoms after the end of the first year of life was significantly better than that of patients whose illness started in infancy. Our data confirm that the severity of chronic granulomatous disease is not uniform, and that the prognosis for long term survival is better than that suggested in earlier reports. […] Early onset may be a poor prognostic sign and invasive aspergillosis is a life threatening complication. In the absence of curative treatment, trials to assess the effectiveness of interferon gamma are necessary and early antenatal diagnosis should be offered to as many affected families as possible.
#11 Chronic Granulomatous Disease: Practice Essentials, Background, Pathophysiology
https://emedicine.medscape.com/article/1116022-overview
The long-term survival of patients who develop symptoms after the end of the first year of life is significantly better than that of patients whose illness starts in infancy. Survival rates are variable but improving; approximately 50% of patients survive to age 30-40 years. Infections are less common in adults than in children, but the propensity for severe life-threatening bacterial infections persists throughout life. […] Fungal infections remain a major determinant of survival in chronic granulomatous disease (CGD). Morbidity secondary to infection or granulomatous complications remains significant for many patients, particularly those with the X-linked form. X-linked patients generally have more severe disease, and this is generally in those with lower residual superoxide production. Survival in CGD has increased over the years, but infections are still major causes of morbidity and mortality. Currently, the annual mortality rate is 1.5% per year for persons with autosomal recessive CGD and 5% for those with X-linked CGD.
#12 Chronic Granulomatous Disease: Practice Essentials, Background, Pathophysiology
https://emedicine.medscape.com/article/1116022-overview
The long-term survival of patients who develop symptoms after the end of the first year of life is significantly better than that of patients whose illness starts in infancy. Survival rates are variable but improving; approximately 50% of patients survive to age 30-40 years. Infections are less common in adults than in children, but the propensity for severe life-threatening bacterial infections persists throughout life. […] Fungal infections remain a major determinant of survival in chronic granulomatous disease (CGD). Morbidity secondary to infection or granulomatous complications remains significant for many patients, particularly those with the X-linked form. X-linked patients generally have more severe disease, and this is generally in those with lower residual superoxide production. Survival in CGD has increased over the years, but infections are still major causes of morbidity and mortality. Currently, the annual mortality rate is 1.5% per year for persons with autosomal recessive CGD and 5% for those with X-linked CGD.
#13 Chronic Granulomatous Disease: Practice Essentials, Background, Pathophysiology
https://emedicine.medscape.com/article/1116022-overview
The long-term survival of patients who develop symptoms after the end of the first year of life is significantly better than that of patients whose illness starts in infancy. Survival rates are variable but improving; approximately 50% of patients survive to age 30-40 years. Infections are less common in adults than in children, but the propensity for severe life-threatening bacterial infections persists throughout life. […] Fungal infections remain a major determinant of survival in chronic granulomatous disease (CGD). Morbidity secondary to infection or granulomatous complications remains significant for many patients, particularly those with the X-linked form. X-linked patients generally have more severe disease, and this is generally in those with lower residual superoxide production. Survival in CGD has increased over the years, but infections are still major causes of morbidity and mortality. Currently, the annual mortality rate is 1.5% per year for persons with autosomal recessive CGD and 5% for those with X-linked CGD.
#14 Chronic Granulomatous Disease: Practice Essentials, Background, Pathophysiology
https://emedicine.medscape.com/article/1116022-overview
The long-term survival of patients who develop symptoms after the end of the first year of life is significantly better than that of patients whose illness starts in infancy. Survival rates are variable but improving; approximately 50% of patients survive to age 30-40 years. Infections are less common in adults than in children, but the propensity for severe life-threatening bacterial infections persists throughout life. […] Fungal infections remain a major determinant of survival in chronic granulomatous disease (CGD). Morbidity secondary to infection or granulomatous complications remains significant for many patients, particularly those with the X-linked form. X-linked patients generally have more severe disease, and this is generally in those with lower residual superoxide production. Survival in CGD has increased over the years, but infections are still major causes of morbidity and mortality. Currently, the annual mortality rate is 1.5% per year for persons with autosomal recessive CGD and 5% for those with X-linked CGD.
#15 Chronic Granulomatous Disease: Practice Essentials, Background, Pathophysiology
https://emedicine.medscape.com/article/1116022-overview
Since the advent of prophylactic antibiotics, antifungals, and interferon-gamma (INF-gamma), the prognosis for patients with CGD has improved. Patients living to their 30s and 40s is now common. […] Patients with CGD and modest residual production of reactive oxygen intermediates (ROIs) have significantly less severe illness and a greater likelihood of long-term survival than patients with little residual ROI production. The production of residual ROI is predicted by the specific NADPH oxidase mutation, regardless of the specific gene affected, and is a predictor of survival in patients with CGD.
#16 A Review of Chronic Granulomatous Disease
https://pmc.ncbi.nlm.nih.gov/articles/PMC5709447/
Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by defects in any of the five subunits of the NADPH oxidase complex responsible for the respiratory burst in phagocytic leukocytes. […] The implementation of routine antimicrobial prophylaxis and the advent of azole antifungals has considerably improved overall survival. Nevertheless, life expectancy remains decreased compared to the general population. […] At present, hematopoietic stem cell transplantation (HCT) is the only curative treatment, and transplantation outcomes have improved over the last few decades with overall survival rates now 90% in children less than 14 years of age. […] The current evidence suggests that myeloablative conditioning results in more durable myeloid engraftment but with increased toxicity and high rates of graft-versus-host disease.
#17 Chronic Granulomatous Disease: Symptoms & Treatment
https://my.clevelandclinic.org/health/diseases/21157-chronic-granulomatous-disease-cgd
The outlook is generally very good. Healthcare providers can usually manage symptoms of CGD and prevent serious infections. Treatment may continue indefinitely to keep infections and inflammation from becoming severe. […] With ongoing treatment and support, many people with CGD live active and fulfilling lives. Prompt treatment is necessary so that your provider can treat infections before they become severe or life-threatening. […] A genetic condition like CGD shouldn’t affect your quality of life. If you’re a parent with a child who has CGD, know that this isn’t your fault and that your child still has an excellent prognosis for living a long and happy life.
#18 A Review of Chronic Granulomatous Disease
https://pmc.ncbi.nlm.nih.gov/articles/PMC5709447/
Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by defects in any of the five subunits of the NADPH oxidase complex responsible for the respiratory burst in phagocytic leukocytes. […] The implementation of routine antimicrobial prophylaxis and the advent of azole antifungals has considerably improved overall survival. Nevertheless, life expectancy remains decreased compared to the general population. […] At present, hematopoietic stem cell transplantation (HCT) is the only curative treatment, and transplantation outcomes have improved over the last few decades with overall survival rates now 90% in children less than 14 years of age. […] The current evidence suggests that myeloablative conditioning results in more durable myeloid engraftment but with increased toxicity and high rates of graft-versus-host disease.
#19 A Review of Chronic Granulomatous Disease
https://pmc.ncbi.nlm.nih.gov/articles/PMC5709447/
Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by defects in any of the five subunits of the NADPH oxidase complex responsible for the respiratory burst in phagocytic leukocytes. […] The implementation of routine antimicrobial prophylaxis and the advent of azole antifungals has considerably improved overall survival. Nevertheless, life expectancy remains decreased compared to the general population. […] At present, hematopoietic stem cell transplantation (HCT) is the only curative treatment, and transplantation outcomes have improved over the last few decades with overall survival rates now 90% in children less than 14 years of age. […] The current evidence suggests that myeloablative conditioning results in more durable myeloid engraftment but with increased toxicity and high rates of graft-versus-host disease.
#20 A Review of Chronic Granulomatous Disease
https://pmc.ncbi.nlm.nih.gov/articles/PMC5709447/
Survival following HCT has increased from approximately 85% before 2000 to greater than 90% in recent reports, and outcomes have been encouraging regardless of the donor source. […] As such, HCT should be considered for all patients with CGD regardless of sex, genetic mutation, and clinical manifestations. […] Ultimately, as HCT becomes more widely available and better tolerated, we expect overall life expectancy for patients with CGD to increase substantially over the next several years.
#21 A Review of Chronic Granulomatous Disease
https://pmc.ncbi.nlm.nih.gov/articles/PMC5709447/
Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by defects in any of the five subunits of the NADPH oxidase complex responsible for the respiratory burst in phagocytic leukocytes. […] The implementation of routine antimicrobial prophylaxis and the advent of azole antifungals has considerably improved overall survival. Nevertheless, life expectancy remains decreased compared to the general population. […] At present, hematopoietic stem cell transplantation (HCT) is the only curative treatment, and transplantation outcomes have improved over the last few decades with overall survival rates now 90% in children less than 14 years of age. […] The current evidence suggests that myeloablative conditioning results in more durable myeloid engraftment but with increased toxicity and high rates of graft-versus-host disease.
#22 A Review of Chronic Granulomatous Disease
https://pmc.ncbi.nlm.nih.gov/articles/PMC5709447/
Survival following HCT has increased from approximately 85% before 2000 to greater than 90% in recent reports, and outcomes have been encouraging regardless of the donor source. […] As such, HCT should be considered for all patients with CGD regardless of sex, genetic mutation, and clinical manifestations. […] Ultimately, as HCT becomes more widely available and better tolerated, we expect overall life expectancy for patients with CGD to increase substantially over the next several years.
#23 Chronic Granulomatous Disease: Symptoms & Treatment
https://my.clevelandclinic.org/health/diseases/21157-chronic-granulomatous-disease-cgd
The outlook is generally very good. Healthcare providers can usually manage symptoms of CGD and prevent serious infections. Treatment may continue indefinitely to keep infections and inflammation from becoming severe. […] With ongoing treatment and support, many people with CGD live active and fulfilling lives. Prompt treatment is necessary so that your provider can treat infections before they become severe or life-threatening. […] A genetic condition like CGD shouldn’t affect your quality of life. If you’re a parent with a child who has CGD, know that this isn’t your fault and that your child still has an excellent prognosis for living a long and happy life.
#24 Chronic Granulomatous Disease: Symptoms & Treatment
https://my.clevelandclinic.org/health/diseases/21157-chronic-granulomatous-disease-cgd
The outlook is generally very good. Healthcare providers can usually manage symptoms of CGD and prevent serious infections. Treatment may continue indefinitely to keep infections and inflammation from becoming severe. […] With ongoing treatment and support, many people with CGD live active and fulfilling lives. Prompt treatment is necessary so that your provider can treat infections before they become severe or life-threatening. […] A genetic condition like CGD shouldn’t affect your quality of life. If you’re a parent with a child who has CGD, know that this isn’t your fault and that your child still has an excellent prognosis for living a long and happy life.
#25 Chronic Granulomatous Disease: Symptoms & Treatment
https://my.clevelandclinic.org/health/diseases/21157-chronic-granulomatous-disease-cgd
The outlook is generally very good. Healthcare providers can usually manage symptoms of CGD and prevent serious infections. Treatment may continue indefinitely to keep infections and inflammation from becoming severe. […] With ongoing treatment and support, many people with CGD live active and fulfilling lives. Prompt treatment is necessary so that your provider can treat infections before they become severe or life-threatening. […] A genetic condition like CGD shouldn’t affect your quality of life. If you’re a parent with a child who has CGD, know that this isn’t your fault and that your child still has an excellent prognosis for living a long and happy life.
#26 Chronic Granulomatous Disease: Symptoms & Treatment
https://my.clevelandclinic.org/health/diseases/21157-chronic-granulomatous-disease-cgd
The outlook is generally very good. Healthcare providers can usually manage symptoms of CGD and prevent serious infections. Treatment may continue indefinitely to keep infections and inflammation from becoming severe. […] With ongoing treatment and support, many people with CGD live active and fulfilling lives. Prompt treatment is necessary so that your provider can treat infections before they become severe or life-threatening. […] A genetic condition like CGD shouldn’t affect your quality of life. If you’re a parent with a child who has CGD, know that this isn’t your fault and that your child still has an excellent prognosis for living a long and happy life.
#27 Prognosis of chronic granulomatous disease – PubMed
https://pubmed.ncbi.nlm.nih.gov/2221966/
The records of 28 patients with chronic granulomatous disease born over a 32 year period were reviewed. Nine patients were known to have died, in most cases of progressive suppurative infection. Actuarial analysis showed 50% survival through the third decade of life. The long term survival of patients developing symptoms after the end of the first year of life was significantly better than that of patients whose illness started in infancy. Our data confirm that the severity of chronic granulomatous disease is not uniform, and that the prognosis for long term survival is better than that suggested in earlier reports. […] Early onset may be a poor prognostic sign and invasive aspergillosis is a life threatening complication. In the absence of curative treatment, trials to assess the effectiveness of interferon gamma are necessary and early antenatal diagnosis should be offered to as many affected families as possible.
#28 Prognosis of chronic granulomatous disease – PubMed
https://pubmed.ncbi.nlm.nih.gov/2221966/
The records of 28 patients with chronic granulomatous disease born over a 32 year period were reviewed. Nine patients were known to have died, in most cases of progressive suppurative infection. Actuarial analysis showed 50% survival through the third decade of life. The long term survival of patients developing symptoms after the end of the first year of life was significantly better than that of patients whose illness started in infancy. Our data confirm that the severity of chronic granulomatous disease is not uniform, and that the prognosis for long term survival is better than that suggested in earlier reports. […] Early onset may be a poor prognostic sign and invasive aspergillosis is a life threatening complication. In the absence of curative treatment, trials to assess the effectiveness of interferon gamma are necessary and early antenatal diagnosis should be offered to as many affected families as possible.
#29 Chronic Granulomatous Disease: Symptoms & Treatment
https://my.clevelandclinic.org/health/diseases/21157-chronic-granulomatous-disease-cgd
The outlook is generally very good. Healthcare providers can usually manage symptoms of CGD and prevent serious infections. Treatment may continue indefinitely to keep infections and inflammation from becoming severe. […] With ongoing treatment and support, many people with CGD live active and fulfilling lives. Prompt treatment is necessary so that your provider can treat infections before they become severe or life-threatening. […] A genetic condition like CGD shouldn’t affect your quality of life. If you’re a parent with a child who has CGD, know that this isn’t your fault and that your child still has an excellent prognosis for living a long and happy life.